Editas Medicine, which is developing gene editing therapies based on CRISPR/Cas9 technology, raised $94 million by offering 5.9 million shares at $16, the low end of the range of $16 to $18. Editas Medicine plans to list on the Nasdaq under the symbol EDIT. Morgan Stanley and J.P. Morgan acted as lead managers on the deal.
